Lamivudine therapy for chronic hepatitis B: A six-month randomized dose- ranging study

Nevens, Frederik; Main, Janice; Honkoop, Pieter; Tyrrell, D. Lorne; Barber, Judy; Sullivan, Mark; Fevery, Johan; Man, Robert A. de; Thomas, H.C.

doi:10.1053/gast.1997.v113.pm9322520

Cited by 271 publications

(217 citation statements)

References 1 publication

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…Suppression of HBV DNA by lamivudine has been demonstrated in studies of patients chronically infected with HBV [33][34][35]. In cases of co-infected HBV-HIV patients who received lamivudine as part of their antiretroviral treatment, loss of HBV DNA after one year of treatment was observed in 96.3% of patients when assessed by molecular hybridization and 88.5% of patients assessed by PCR [36].…”

Section: Discussionmentioning

confidence: 98%

Occult hepatitis B virus infection in immunocompromised patients

Jardim¹,

Gonçales²,

Pereira³

et al. 2008

Braz J Infect Dis

View full text Add to dashboard Cite

Occult hepatitis B infection is characterized by hepatitis B virus (HBV) DNA in the serum in the absence of hepatitis B surface antigen (HBsAg). We assessed occult HBV infection prevalence in two groups of immunocompromised patients (maintenance hemodialysis patients and HIV-positive patients) presenting HBsAgnegative and anti-HBc positive serological patterns, co-infected or not by HCV. Thirty-four hemodialysis anti-HIV negative patients, 159 HIV-positive patients and 150 blood donors who were anti-HBc positive (control group) were selected. HBV-DNA was detected by nested-PCR. Occult hepatitis B infection was not observed in the hemodialysis patients group but was found in 5% of the HIV-patients and in 4% of the blood donors. Immunosuppression in HIV positive patients was not a determining factor for occult HBV infection. In addition, no significant relationship between HBV-DNA and HCV co-infection in the HIV-positive patient group was found. A lack of significant associations was also observed between positivity for HBV-DNA and CD4 count, viral load and previous lamivudine treatment in these HIV-positive patients.

show abstract

Section: Discussionmentioning

confidence: 98%

Occult hepatitis B virus infection in immunocompromised patients

Jardim¹,

Gonçales²,

Pereira³

et al. 2008

Braz J Infect Dis

View full text Add to dashboard Cite

show abstract

“…Previously, a pilot study demonstrated the lack of efficacy of lamivudine monotherapy against HDVinfection (9). In some cases of HDV infection, quantitative HBsAg concentrations decreased during lamivudine treatment (2). It has been shown that HBVenvelope protein plays an important role in HDV particle assembly (18), suggesting that reduction of HBsAg by lamivudine therapy could help reduce HDV-induced hepatic injury.…”

Section: Discussionmentioning

confidence: 99%

“…Presently, lamivudine is one of the most promising agents for the treatment of HBV, due to its ability to rapidly suppress elevations in serum HBVDNAlevels in patients with chronic hepatitis B (CHB); in one study, such suppression occurred in 80%of patients after 6 months of therapy (2). However, it is well known that there have been increasing reports of emergenceof drug-resistant strains of HBVafter prolonged lamivudine monotherapy (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Chronic Hepatitis B with Flare Due to Co-infection of Hepatitis Delta Virus during Lamivudine Therapy

et al. 2003

View full text Add to dashboard Cite

In 1997, a 27-year-old homosexual mancontracted acute hepatitis B that developed into chronic hepatitis. Because of repeated flares, administration of lamivudine was started in March 2002. Hepatitis B virus (HBV) DNA immediately decreased, but the serum level of alanine aminotransferase gradually increased. Drug-induced hepatitis due to lamivudine was excluded. It was suspected that the progression of liver damagewas caused by hepatitis delta virus (HDV), because the patient was positive for both anti-HDV antibody and HDVRNA.Coinfection of HDVshould be considered a possibility if liver injury is not improved by lamivudine therapy. (Internal Medicine 42: 581-586, 2003)

show abstract

“…Update of Liver Disease hibitor of DNApolymerase of HBV.The administration of lamivudine produces a rapid and profound decrease in serum HBVDNAlevels in patients with chronic hepatitis B, and rarely causes severe adverse effects in the patients (8,9). However, the effect is not sustained, and few patients clear HBeAg.…”

Section: Inte Rfe Ronsmentioning

confidence: 99%